|
 
- 现金
- 17064 元
- 精华
- 12
- 帖子
- 9399
- 注册时间
- 2007-6-26
- 最后登录
- 2017-11-25
|
Drug Watch
Compounds in Development for Chronic Hepatitis B
Updated October 2016
FAMILY/DRUG NAME MECHANISM COMPANY WEBSITE USA STATUS
Interferons: Mimic infection-fighting immune substances naturally produced in the body.
Intron A (Interferon alfa-2b) Immunomodulator Merck, USA merck.com Approved 1991
Pegasys (Peginterferon alfa-2a) Immunomodulator Genentech, USA gene.com Approved 2005
Nucleos(t)ide Analogues: Interfere with viral DNA polymerase used for HBV replication
Epivir (Lamivudine) Inhibits viral DNA polymerase GlaxoSmithKline (GSK) gsk.com Approved 1998
Hepsera (Adefovir dipivoxil) Inhibits viral DNA polymerase Gilead Sciences, USA gilead.com Approved 2002
Baraclude (Entecavir) Inhibits viral DNA polymerase Bristol-Myers Squibb, USA bms.com Approved 2005
Tyzeka (Telbivudine) Inhibits viral DNA polymerase Novartis, USA novartis.com Approved 2006
Viread (Tenofovir) Inhibits viral DNA polymerase Gilead Sciences gilead.com Approved 2008
Levovir (Clevudine) Inhibits viral DNA polymerase Bukwang, S. Korea bukwang.co.kr Approved 2006 in S. Korea
Zadaxin Immunomodulator SciClone, USA sciclone.com Approved outside USA
DIRECT ACTING ANTIVIRALS: Targets the virus and interferes in the HBV replication process
TDF Pro Drugs: A modified tenofovir drug that can get into liver cells more easily
TAF (Tenofovir alafenamide) Prodrug of tenofovir Gilead Sciences gilead.com Phase III
CMX 157 Prodrug of tenofovir ContraVir, USA contravir.com Phase II
Silencing RNA’s (siRNAs): Interferes and destroys viral RNA
ARB-1467 RNAi gene silencer (1.0) Arbutus Biopharma, Canada arbutusbio.com Phase II
ARC 520 RNAi gene silencer Arrowhead Pharmaceuticals, USA arrowheadpharma.com Phase II
ARC 521 RNAi gene silencer Arrowhead Pharmaceuticals arrowheadpharma.com Phase I
ALN-HBV RNAi gene silencer Alnylam, USA alnylam.com Preclinical
Hepbarna (BB-HB-331) RNAi gene silencer Benitec, Australia benitec.com Preclinical
ARB-1740 RNAi gene silencer (2.0) Arbutus Biopharma arbutusbio.com Preclinical
Lunar-HBV RNAi gene silencer Arcturus, USA with Janssen of J&J arcturusrx.com Preclinical
Entry Inhibitors: Interferes with HBV getting into liver cells
Myrcludex B Entry inhibitor Hepatera, Russia with MYR GmbH, Germany myr-pharma.com Phase II
Capsid Inhibitors: Interferes with the viral DNA protein shield
Morphothiadin (GLS4) Capsid inhibitor HEC Pharma, pharm.hec.cn/en Phase II
PR China
NVR 3-778 Capsid inhibitor Janssen of J&J janssen.com Phase II
RO6864018 Undisclosed Roche roche.com Phase II
AIC 649 Capsid inhibitor AiCuris, Germany aicuris.com Phase I
JNJ56136379 Capsid Inhibitor Janssen of J&J janssen.com Phase I
HBV CpAM Capsid inhibitor Assembly Biosciences, USA assemblybio.com Preclinical
AB-423 Capsid inhibitor Arbutus Biopharma arbutusbio.com Preclinical
HBsAg Inhibitors: Interferes with production of HBV surface antigen (sAg)
Rep 2139 sAg inhibitor REPLICor, Canada replicor.com Phase II
Rep 2165 sAg inhibitor REPLICor replicor.com Phase II
RO7020322 (RG7834) sAg inhibitor Roche roche.com Phase I
Blumberg 259 sAg inhibitor Blumberg Institute, USA blumberginstitute.org Preclinical
Antisense Molecules: Binds to the viral mRNA to prevent it from turning into viral protein
IONIS-HBVRx (GSK3228836) Viral protein inhibitor Ionis Pharma, USA with GSK ionispharma.com Phase I
IONIS-HBVLRx (GSK33389404) Viral protein inhibitor Ionis Pharma with GSK ionispharma.com Phase I
INDIRECT ACTING ANTIVIRALS: Targets the human immune system to attack the HBV virus
Therapeutic Vaccines: Vaccine technology used to stimulate the immune system as a treatment
GS 4774 Therapeutic vaccine Gilead with GlobeImmune, USA gilead.com Phase II
INO-1800 Therapeutic vaccine Inovio, USA inovio.com Phase I
HB-110 Therapeutic vaccine Ichor, USA with Janssen ichorms.com Phase I
TG1050 Therapeutic vaccine Transgene, France transgene.com Phase I
HepTcell Therapeutic vaccine Altimmune, USA altimmune.com Phase I
TomegaVax HBV Therapeutic vaccine TomegaVax, USA tomegavax.com Preclinical
Innate Immune Defense Pathway: Compounds that activate the innate immune system
GS 9620 TLR-7 agonist Gilead Sciences gilead.com Phase II
RG7795 (ANA773) TLR-7 agonist Roche roche.com Phase II
SB9200 RIG -1 and NOD2 agonist Spring Bank Pharmaceuticals, USA springbankpharm.com Phase II
Blumberg STING STING agonist Blumberg Institute blumberginstitute.org Preclinical
Host Acting Pathway: Compounds that induce programmed cell death (apoptosis)
Birinapant (TL32711) SMAC Inhibitor TetraLogic, USA tetralogicpharma.com Phase I
EYP001 FXR agonist Enyo Pharma, France enyopharma.com Phase I
CRV 431 (CPI 431-32) Ciclofillin inhibitor ContraVir contravir.com Preclinical
HEPATITIS DELTA VIRUS (HDV)
Myrcludex B Entry inhibitor MYR-GmbH myr-pharma.com Phase II
Lonafarnib Prenylation inhibitor Eiger Biopharma, USA eigerbio.com Phase II
Pegylated Interferon Lambda Immunomodulator Eiger Biopharma, USA eigerbio.com Phase II
Rep 2139 HBsAg inhibitor REPLICor replicor.com Phase II
ALN-HDV RNAi gene silencer Alnylam alnylam.com Preclinical
|
-
总评分: 现金 + 31
查看全部评分
|
发表于 2016-10-29 20:07
